GHRP-2

GHRP-2, also known as pralmorelin, is one of the few peptides in the fitness and longevity market that has a legitimate clinical identity. In Japan it is an approved diagnostic agent, given as a single 100 microgram intravenous dose to test pituitary growth hormone reserve [2]. A 2022 review in the Journal of the Endocrine Society describes its clinical usefulness in evaluating hypothalamic-pituitary disorders [3], and a 2024 study confirmed robust and reproducible GH responses in adolescents [4]. This is not a compound whose pharmacology is in doubt.

Mechanistically, GHRP-2 is a synthetic hexapeptide agonist at GHS-R1a, the growth hormone secretagogue receptor that also binds the endogenous hormone ghrelin. Activating that receptor triggers pituitary GH release through a pathway separate from growth hormone releasing hormone, which is why GHRP-class peptides and GHRH analogues such as sermorelin or CJC-1295 produce a larger combined response than either alone. The peptide's D-amino acid content makes it resistant to rapid degradation, so a subcutaneous dose produces a usable pulse.

Because it is a ghrelin mimetic, its effects extend beyond growth hormone. A 2005 study in the Journal of Clinical Endocrinology and Metabolism showed that GHRP-2 increases food intake in healthy men, with subjects eating substantially more at a test meal after infusion [1]. A 2006 study in Obesity confirmed the same appetite effect in obese subjects. Animal work published in Regulatory Peptides showed that GHRP-2 also stimulates ACTH secretion and synthesis, and human studies have documented cortisol and prolactin increases. Anyone framing GHRP-2 as a clean, selective GH pulse is describing ipamorelin, not this molecule.

The evidence problem is not quality but relevance. Everything solid concerns short-term hormonal response, mostly in diagnostic settings measured over minutes to hours. There is no trial of GHRP-2 for body composition over months, no trial for muscle strength or function, no trial in sarcopenia, and no trial with any ageing or healthspan endpoint. The gap between "reliably raises GH" and "improves outcomes in older adults" is the entire question, and no one has attempted to close it for this compound.

That gap is more uncomfortable than it first appears, because the ageing biology points in an awkward direction. Across model organisms, reduced growth hormone and IGF-1 signalling is one of the most reproducible lifespan-extending manipulations known: GH receptor knockout mice are among the longest-lived laboratory mice, and humans with Laron syndrome, who have GH receptor deficiency, show unusually low rates of cancer and diabetes. Chronically stimulating the same axis in the hope of longevity benefit runs against that literature. Short-term GH elevation may still be useful for specific clinical goals such as recovery or preserving lean mass during weight loss, but the longevity framing used in marketing is not supported and may be backwards.

Safety follows predictably from the mechanism. Appetite stimulation is not a side effect but the expected pharmacology, and for someone trying to control body weight it is a substantial practical problem. Sustained GH elevation brings fluid retention, joint aches, carpal tunnel symptoms and paraesthesia, all familiar from GH replacement therapy. The metabolic concern is insulin sensitivity: GH is counter-regulatory to insulin, and chronic elevation can raise fasting glucose and worsen glycaemic control, which matters for anyone with prediabetes or diabetes. Elevated IGF-1 also carries a theoretical proliferative risk, which is why active or prior malignancy is a reasonable contraindication. Cortisol and prolactin elevation add further complexity for anyone with hormonal issues.

The regulatory position is unambiguous in two respects. GHRP-2 is prohibited at all times in sport under the World Anti-Doping Agency list as a growth hormone secretagogue, and it has been detected in supplements sold to athletes, which is how several inadvertent doping cases have arisen; a 2010 paper in Drug Testing and Analysis documented GHRP-2 in a nutritional supplement [5]. Separately, the FDA has flagged GHRP-2 among bulk drug substances presenting significant safety risks for use in compounding, which removed a route by which US clinics previously supplied it.

Our position: GHRP-2 is tier 3, which reflects real human data at the wrong endpoints rather than uncertainty about whether the drug does anything. It reliably raises growth hormone. It also reliably raises appetite, cortisol and prolactin, has no long-term safety file in healthy adults, is banned in sport, and sits on the wrong side of the strongest longevity signal in comparative biology. For a competitive athlete it is disqualifying. For someone pursuing healthspan, the burden of proof has not been met.